Top

Published in:

01-10-2011 | Original Article

Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma

Authors: Mona A. A. Zaki, Naoki Wada, Junichiro Ikeda, Hirohiko Shibayama, Koji Hashimoto, Tamotsu Yamagami, Yoichi Tatsumi, Machiko Tsukaguchi, Hironori Take, Mitsuru Tsudo, Eiichi Morii, Katsuyuki Aozasa

Published in: Virchows Archiv | Issue 4/2011

Abstract

To evaluate roles of tumor-associated macrophages (TAMs) for prognosis of classical Hodgkin lymphoma (CHL). Expression of markers for TAMs, CD68, HLA-DR, CD163, HLA-DR/CD68 (M1), and CD163/CD68 (M2) was immunohistochemically examined in 82 cases with CHL. Positively stained cells were counted and correlation of number of TAMs and patients’ survival time was analyzed. Number of CD163+ cells and M2 cells was significantly correlated with shorter overall survival (P < 0.05), while it was marginally significant for CD68+ cells (P = 0.0827). HLA-DR + cells and M1 cells showed no significant correlation with overall survival. When confined to mixed cellularity subtype, number of M1 cells was correlated with favorable prognosis (P < 0.05), while M2 did not (P = 0.7). Older age and male sex were unfavorable factors for prognosis. At multivariate analysis, number of CD163+ cells, M2+ cells, and age were independent factors for poor overall survival (P = 0.03, 0.02, and 0.01, respectively). CD163+ cells and M2 cells might work to be tumor promotive in CHL. M1 cells might be tumor suppressive in mixed cellularity type.

Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van’t Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 357:1916–1927PubMedCrossRef

Ansell SM, Armitage JO (2006) Management of Hodgkin lymphoma. Mayo Clin Proc 81:419–426PubMedCrossRef

Lewis CE, Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66:605–612PubMedCrossRef

Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD (2010) Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med 362:875–885PubMedCrossRef

Buddingh EP, Kuijjer ML, Duim RA, Bürger H, Agelopoulos K, Myklebost O, Serra M, Mertens F, Hogendoorn PC, Lankester AC, Cleton-Jansen AM (2011) Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res 17:2110–2119PubMedCrossRef

Dai F, Liu L, Che G, Yu N, Pu Q, Zhang S, Ma J, Ma L, You Z (2010) The number and microlocalization of tumor-associated immune cells are associated with patient’s survival time in non-small cell lung Cancer. BMC Cancer. 10: 220. Available at: http://www.biomedcentral.com/1471-2407/10/220 PubMedCrossRef

Jensen TO, Schmidt H, Møller HJ, Høyer M, Maniecki MB, Sjoegren P, Christensen IJ, Steiniche T (2009) Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol 7:3330–3337CrossRef

Ma J, Liu L, Che G, Yu N, Dai F, You Z. (2010) The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer. 10:112. Available at: http://www.biomedcentral.com/1471-2407/10/112 PubMedCrossRef

Glaser SL, Hsu JL (2002) Hodgkin’s disease in Asians: incidence patterns and risk factors in population-based data. Leuk Res 26:261–269PubMedCrossRef

10.

Aozasa K, Ueda T, Tamai M, Tsujimura T (1986) Hodgkin’s disease in Osaka, Japan (1964–1985). Eur J Cancer Clin Oncol 22:1117–1119PubMedCrossRef

11.

Tjiu JW, Chen JS, Shun CT, Lin SJ, Liao YH, Chu CY, Tsai TF, Chiu HC, Dai YS, Inoue H, Yang PC, Kuo ML, Jee SH (2009) Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J Invest Dermatol 129:1016–1025PubMedCrossRef

12.

Lamagna C, Aurrand-Lions M, Imhof BA (2006) Dual role of macrophages in tumor growth and angiogenesis. J Leuk Biol 80:705–713CrossRef

13.

Al-Sarireh B, Eremin O (2004) Tumor-associated macrophages (TAMS): disordered function, immune suppression and progressive tumour growth. J R Coll Surg Edinb 5:1–16

14.

Caux C, Vanbervliet B, Massacrier C, Dezutter-Dambuyant C, de Saint-Vis B, Jacquet C, Yoneda K, Imamura S, Schmitt D, Banchereau J (1996) CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF + TNF alpha. J Exp Med 184:695–706PubMedCrossRef

15.

Nakamura H, Saji H, Aute I, Kawasaki N, Hosaka M, Ogata A, Saijo T, Kato H (2003) Peripheral leukocytes with HLA-DR+/CD8-phenotype are associated with prognosis in patients with lung cancer. Anticancer Res 23:4149–4152PubMed

16.

Maniecki MB, Møller HJ, Moestrup SK, Møller BK (2006) CD163 positive subsets of blood dendritic cells: the scavenging macrophage receptors CD163 and CD91 are coexpressed on human dendritic cells and monocytes. Immunobiology 211:407–417PubMedCrossRef

17.

Kamper P, Bendix K, Hamilton-Dutoit S, Honoré B, Nyengaard JR, d’Amore F (2011) Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein–Barr virus status in classical Hodgkin’s lymphoma. Haematologica 96:269–276PubMedCrossRef

18.

Lee CH, Espinosa I, Vrijaldenhoven S, Subramanian S, Montgomery KD, Zhu S et al (2008) Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res 14:1423–1430PubMedCrossRef

Title: Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma
Authors: Mona A. A. Zaki
Naoki Wada
Junichiro Ikeda
Hirohiko Shibayama
Koji Hashimoto
Tamotsu Yamagami
Yoichi Tatsumi
Machiko Tsukaguchi
Hironori Take
Mitsuru Tsudo
Eiichi Morii
Katsuyuki Aozasa
Publication date: 01-10-2011
Publisher: Springer-Verlag
Published in: Virchows Archiv / Issue 4/2011
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-011-1140-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2011

Expression of JL1 in Burkitt lymphoma is associated with improved overall survival

Expression of the ribonucleases Drosha, Dicer, and Ago2 in colorectal carcinomas

MTA1 expression correlates significantly with cigarette smoke in non-small cell lung cancer

Epithelial marker expression does not rule out a diagnosis of Ewing’s sarcoma family of tumours

The role of tumor hypoxia in MUC1-positive breast carcinomas

Angiogenesis in triple-negative adenoid cystic carcinomas of the breast